
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SABS)
WebsitePrice
Market cap
Next catalystPRISE-hATG first-patient dosing expected in Q4 2026SAB-142 — PRISE-hATG, investigator-led · Trial initiationCompany release ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
Other pipelines
PreINDP1P2P3FilingApproved
History / paused
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved